Eli Lilly and Company (NYSE:LLY) Shares Sold by Intech Investment Management LLC

Intech Investment Management LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 2.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 224,542 shares of the company's stock after selling 5,453 shares during the period. Eli Lilly and Company accounts for approximately 2.2% of Intech Investment Management LLC's portfolio, making the stock its 6th largest position. Intech Investment Management LLC's holdings in Eli Lilly and Company were worth $198,931,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of LLY. International Assets Investment Management LLC boosted its stake in Eli Lilly and Company by 87,091.7% in the third quarter. International Assets Investment Management LLC now owns 12,463,182 shares of the company's stock valued at $11,041,631,000 after acquiring an additional 12,448,888 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Eli Lilly and Company by 5.0% in the second quarter. Dimensional Fund Advisors LP now owns 3,581,075 shares of the company's stock valued at $3,242,296,000 after acquiring an additional 171,595 shares in the last quarter. Janus Henderson Group PLC boosted its stake in Eli Lilly and Company by 7.3% in the first quarter. Janus Henderson Group PLC now owns 3,575,684 shares of the company's stock valued at $2,781,613,000 after acquiring an additional 243,729 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in Eli Lilly and Company by 0.7% in the second quarter. Ameriprise Financial Inc. now owns 3,027,901 shares of the company's stock valued at $2,741,832,000 after acquiring an additional 22,392 shares in the last quarter. Finally, American Century Companies Inc. boosted its stake in Eli Lilly and Company by 5.1% in the second quarter. American Century Companies Inc. now owns 2,069,881 shares of the company's stock valued at $1,874,029,000 after acquiring an additional 100,426 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Trading Up 3.2 %

Shares of Eli Lilly and Company stock opened at $753.41 on Thursday. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The stock has a market cap of $715.23 billion, a PE ratio of 81.45, a price-to-earnings-growth ratio of 2.76 and a beta of 0.43. The company has a 50-day moving average of $872.25 and a two-hundred day moving average of $869.98.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion during the quarter, compared to analysts' expectations of $12.09 billion. During the same period last year, the business posted $0.10 earnings per share. The company's quarterly revenue was up 20.4% on a year-over-year basis. On average, research analysts anticipate that Eli Lilly and Company will post 13.21 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.69%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 56.22%.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the firm's stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,480 shares of the company's stock, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 0.13% of the company's stock.

Analyst Ratings Changes

LLY has been the subject of several research analyst reports. Citigroup upped their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a "buy" rating in a research note on Friday, October 25th. Berenberg Bank increased their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a "buy" rating in a research note on Wednesday, August 14th. JPMorgan Chase & Co. increased their target price on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an "overweight" rating in a research note on Friday, September 13th. Wolfe Research initiated coverage on shares of Eli Lilly and Company in a research note on Friday, November 15th. They set an "outperform" rating and a $1,000.00 target price for the company. Finally, Truist Financial increased their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a "buy" rating in a research note on Thursday, October 10th. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,007.94.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.